

PRESS RELEASE**NANOBIOTIX ANNOUNCES PRESENTATION OF DATA FROM TWO PHASE 1 STUDIES EVALUATING JNJ-1900 (NBTXR3) AT THE EUROPEAN LUNG CANCER CONFERENCE**

- Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, locoregional recurrent NSCLC to be presented by principal investigator Dr. Saumil Gandhi at 8:00 AM EDT / 1:00 PM CET on Friday March 28th, 2025
- Data evaluating safety and injection feasibility from a Phase 1 study of JNJ-1900 (NBTXR3) in combination nivolumab or pembrolizumab for the treatment of patients with lung metastases from NSCLC or other solid tumors to be presented by principal investigator Dr. Colette Shen at 8:00 AM EDT / 1:00 PM CET on Friday March 28th, 2025

Paris, France; Cambridge, Massachusetts (USA); March 20, 2025 – [NANOBIOTIX](#) (Euronext: NANO — NASDAQ: NBTX – the “**Company**”), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced poster presentations from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) for patients with lung cancer (NSCLC) to be presented at the 2025 European Lung Cancer Conference (“ELCC”).

ABSTRACT #207P: Phase 1 Study of Reirradiation (“ReRT”) with NBTXR3 (JNJ-1900) for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (“NSCLC”)

Saumil J. Gandhi, MD, PhD,¹ Enoch Chang, MD,¹ Aileen Chen, MD,¹ Stephen G. Chun, MD,¹ Steven H. Lin, MD, PhD,¹ Rachel C. Maguire, BS,¹ Matthew S. Ning, MD, MPH,¹ Julianna K. Bronk, MD, PhD,¹ David Qian, MD,¹ Joe Y. Chang, MD, PhD,¹ James W. Welsh, MD,¹ Zhongxing Liao, MD,¹ Rahul A. Sheth, MD,² Roberto F. Casal, MD³

¹Department of Thoracic Radiation Oncology, UT MD Anderson Cancer Center, ²Department of Interventional Radiology, UT MD Anderson Cancer Center, ³Department of Pulmonary Medicine, UT MD Anderson Cancer Center

ABSTRACT #255P: NBTXR3 (JNJ-1900) Activated by SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Patients with Lung Metastases from NSCLC or Other Solid Tumors in the Phase 1 Trial Study 1100

Colette Shen¹, Aditya Juloori², William A Stokes³, Jason Akulian¹, Jared Weiss¹, Kedar Kirtane⁴, Laurent Mayrargue⁵, David Rolando⁵, Romain Gineste⁵, Omar I. Vivar⁵, George Q. Yang⁴, Jimmy Caudell⁴, Ammar Sukari⁶, Nabil F Saba³, Septimiu Murgu², Ari Rosenberg²

¹University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA, ²The University of Chicago, Chicago, Illinois, USA,

³Winship Cancer Institute of Emory University, Atlanta, Georgia, USA, ⁴Moffitt Cancer Center, Tampa, Florida, USA, ⁵Nanobiotix, Paris, France, ⁶Karmanos Cancer Institute, Detroit, MI, USA

About JNJ-1900 (NBTXR3)

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug

Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study.

Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson company.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on [LinkedIn](#) and [Twitter](#)

Disclaimer

This press release contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceeds therefrom, and the period of time through which the Company anticipates its financial resources will be adequate to support operations. Words such as "expects", "intends", "can", "could", "may", "might", "plan", "potential", "should" and "will" or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company's management's current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix's business and financial performance, which include the risk that assumptions underlying the Company's cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix's Annual Report on Form 20-F filed with the SEC on April 24, 2024 under "Item 3.D. Risk Factors", in Nanobiotix's 2023 universal registration document filed with the AMF on April 24, 2024, in Nanobiotix' 2024 semi-annual report under the caption "Supplemental Risk Factor" filed with the SEC on Form 6-K and with AMF on September 18, 2024, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC's website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Contacts

Nanobiotix

Communications Department

Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com

Investor Relations Department

Craig West
SVP, Investor Relations
+1 (617) 583-0211
investors@nanobiotix.com

Media Relations

France – **HARDY**

Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr

Global – **uncapped Communications**

nanobiotixteam@uncappedcommunications.com

